These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22779693)

  • 1. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.
    Cremonini F; Nicandro JP; Atkinson V; Shringarpure R; Chuang E; Lembo A
    Aliment Pharmacol Ther; 2012 Sep; 36(5):437-48. PubMed ID: 22779693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
    Olden KW; Chey WD; Shringarpure R; Paul Nicandro J; Chuang E; Earnest DL
    Curr Med Res Opin; 2019 Mar; 35(3):461-472. PubMed ID: 30293448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
    Lembo AJ; Olden KW; Ameen VZ; Gordon SL; Heath AT; Carter EG
    Clin Gastroenterol Hepatol; 2004 Aug; 2(8):675-82. PubMed ID: 15290660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
    Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of treatment continuation with alosetron by IBS-D severity criteria.
    Nicandro JP; Shin P; Chuang E
    Curr Med Res Opin; 2012 Mar; 28(3):449-56. PubMed ID: 22313141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
    Chang L; Chey WD; Harris L; Olden K; Surawicz C; Schoenfeld P
    Am J Gastroenterol; 2006 May; 101(5):1069-79. PubMed ID: 16606352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
    Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
    Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
    Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
    Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Fukudo S; Kinoshita Y; Okumura T; Ida M; Akiho H; Nakashima Y; Nishida A; Haruma K
    Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
    Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
    Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
    Andresen V; Montori VM; Keller J; West CP; Layer P; Camilleri M
    Clin Gastroenterol Hepatol; 2008 May; 6(5):545-55. PubMed ID: 18242143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
    Bleser S
    Curr Med Res Opin; 2011 Mar; 27(3):503-12. PubMed ID: 21208139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alosetron and irritable bowel syndrome.
    Mayer EA; Bradesi S
    Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
    Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
    Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
    Chang L; Tong K; Ameen V
    Am J Gastroenterol; 2010 Apr; 105(4):866-75. PubMed ID: 20197759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.